{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-24-092475","form_type":"8-K","ticker":"VRTX","cik":"0000875320","company_name":"VERTEX PHARMACEUTICALS INC / MA","filed_at":"2024-04-11T23:59:59+00:00","discovered_at":"2026-05-14T18:03:22.242793+00:00","generated_at":"2026-06-04T00:15:01.234544+00:00","sec_items":["1.01","8.01","9.01"],"event_type":"m_and_a","sentiment":"neutral","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Vertex to acquire Alpine Immune Sciences for $65 per share in all-cash tender offer","bullets":["Vertex agrees to buy Alpine Immune Sciences at $65/share via tender offer followed by a merger.","Supporting stockholders owning ~25.5% of Alpine shares have committed to tender their shares.","Alpine must pay Vertex a $173M termination fee if deal terminates under specified conditions.","Offer is not subject to a financing condition; expected to close by April 10, 2025 outside date.","Deal includes full vesting of unvested equity awards, which will be cashed out at the offer price."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-24-092475","json":"https://secwatch.observer/filing/0001193125-24-092475.json","markdown":"https://secwatch.observer/filing/0001193125-24-092475.md","text":"https://secwatch.observer/filing/0001193125-24-092475.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/875320/000119312524092475/0001193125-24-092475-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/875320/000119312524092475/d752930d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-04T00:15:01.234544+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"134f92a630596b6087f60ff437ce360e2ea2458d","claim":"VERTEX PHARMACEUTICALS INC / MA entered into Agreement and Plan of Merger with Alpine Immune Sciences, Inc. valued at $65.00 per share (effective 2024-04-10).","evidence_excerpt":"On April 10, 2024, Vertex Pharmaceuticals Incorporated, a Massachusetts corporation (“ Parent ”), Adams Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent (“ Merger Sub ”), and Alpine Immune Sciences, Inc., a Delaware corporation (the “ Company ”), entered into an Agreement and Plan of Merger (the “ Merger Agreement ”).","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/875320/000119312524092475/0001193125-24-092475-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"merger"},{"label":"Counterparty","value":"Alpine Immune Sciences, Inc."},{"label":"Value","value":"$65.00 per share"},{"label":"Effective","value":"2024-04-10"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}